Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion
The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...
Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call
Pushkal Garg; Chief Medical Officer, Executive Vice President - Development and Medical Affairs; Alnylam Pharmaceuticals Inc Jeffrey Poulton; Chief Financial Officer, Executive Vice President; Alnylam ...
Alnylam: Waiting For Regulatory Updates In March
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.
FiercePharma16h
Alnylam touts Amvuttra's potential move into ATTR-CM as a 'market-growth story'
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...